LFMD
LifeMD, Inc.
LFMD lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
LFMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Strong |
LFMD's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LFMD PE Valuation
LFMD has no meaningful PE right now: it lost money over the past year.
LFMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect LFMD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LFMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$0.11 |
| Q2 2026 | -$0.04 | +$0.16 |
| Q1 2026 | $0.06 | +$0.39 |
| Q4 2025 | $0.27 | +$0.80 |
| Q3 2025 | -$0.16 | +$0.48 |
| Q2 2025 | -$0.20 | +$0.50 |
| Q1 2025 | -$0.33 | +$0.41 |
| Q4 2024 | -$0.53 | +$0.17 |
LFMD lost $0.05 per share over the past year, a smaller loss than the year before, but its loss has widened in each of the last three quarters.
LFMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $44.6M | -26% |
| Q2 2026 | $47.3M | -24% |
| Q1 2026 | $50.2M | -24% |
| Q4 2025 | $7.1M | -89% |
| Q3 2025 | $60.2M | +13% |
| Q2 2025 | $62.2M | +23% |
| Q1 2025 | $65.7M | +49% |
| Q4 2024 | $64.3M | +43% |
LFMD's revenue has slid since its 2025 peak: $45M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -6.7 points |
| Q2 2026 | -15% | -14 points |
| Q1 2026 | -18% | -22 points |
| Q4 2025 | -88% | -90 points |
| Q3 2025 | -3.3% | +5.5 points |
| Q2 2025 | -1.5% | +11 points |
| Q1 2025 | 3.9% | +18 points |
| Q4 2024 | 1.6% | +6.4 points |
LFMD's operating margin was −10% last quarter, down 6.7 points from the same quarter a year ago.
LFMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -$176K |
| Q2 2026 | -$7M | -189% |
| Q1 2026 | $339.4K | -88% |
| Q4 2025 | -$3.4M | -356% |
| Q3 2025 | -$944.4K | -116% |
| Q2 2025 | $7.8M | +101% |
| Q1 2025 | $2.9M | -41% |
| Q4 2024 | $1.3M | -76% |
LFMD's free cash flow was −$11M over the past year, against $11M the year before.
LFMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +394K shares |
| 1 year | +4.4% | +2M shares |
| 3 years | +40% | +13.7M shares |
| 5 years | +81% | +21.5M shares |
| Available history | +387% | +38.3M shares |
LFMD has 48M diluted shares, up 4.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | $270,000 |
LFMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
LFMD has more cash than debt.
LFMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 10.1 | Oversold |
LFMD's weekly RSI is 27 (oversold) and its Stochastic is 10 (oversold).
LFMD PE vs Healthcare Sector
| Metric | LFMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFMD has no meaningful PE right now: it lost money over the past year.
LFMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 31% below |
| 20 week MA | $3.14 | 47% below |
| 50 week MA | $3.54 | 53% below |
| 100 week MA | $5.40 | 69% below |
| 200 week MA | $5.43 | 69% below |
LFMD is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
LFMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.65 | $7.84 | +1106% |
| 2021 | $7.84 | $4.32 | -45% |
| 2022 | $4.32 | $2.05 | -53% |
| 2023 | $2.05 | $8.29 | +304% |
| 2024 | $8.29 | $5.22 | -37% |
| 2025 | $5.22 | $3.50 | -33% |
| 2026 YTD | $3.50 | $1.66 | -53% |
LFMD's yearly returns have swung widely, from +1106% in 2020 to −53% in 2022. It's down 53% so far in 2026.